<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2388">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130073</url>
  </required_header>
  <id_info>
    <org_study_id>PA19-0088</org_study_id>
    <secondary_id>NCI-2021-10964</secondary_id>
    <secondary_id>PA19-0088</secondary_id>
    <nct_id>NCT05130073</nct_id>
  </id_info>
  <brief_title>4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer</brief_title>
  <official_title>The Role of a 4-point Therapy Response Score With PET/CT Post Definitive Chemoradiation for Anal Squamous Cell Cancer: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <brief_summary>
    <textblock>
      This study determines whether a positron emission tomography (PET)/computed tomography (CT)&#xD;
      4-point scoring system may predict overall survival for anal squamous cell cancer patients. A&#xD;
      4-point scoring system involving imaging scans may help to predict how patients with anal&#xD;
      squamous cell cancer respond to chemoradiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine whether a PET/CT scoring system in invasive biopsy proven anal squamous cell&#xD;
      carcinoma (SCCA) to be treated with chemoradiation with curative intent (any T any N)&#xD;
      predicts for overall survival (OS).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether a PET/CT scoring system in invasive biopsy proven SCCA to be treated&#xD;
      with definitive chemoradiation with curative intent predicts for progression free survival&#xD;
      (PFS).&#xD;
&#xD;
      II. To determine and validate inter-reader reliability. III. To calculate C-index to evaluate&#xD;
      the prognostic capacity of PET/CT scores for survival.&#xD;
&#xD;
      IV. To determine the association between pre-treatment PET/CT scores after treatment and OS.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To correlate level of standardized uptake value (SUV) pre and post therapy and its&#xD;
      correlation with overall survival.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo PET/CT at baseline and at 3 months post therapy completion. Patients'&#xD;
      medical records are received. Patients are followed up for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>The Kaplan-Meier method will be used. Log rank test will be used to compare OS between positron emission tomography (PET)/computed tomography (CT) negative and positive tumor group. Multivariable Cox proportional hazards models will be fitted to evaluate the association between OS and PET/CT scores, adjusting for the effects of covariates. In addition to positive and negative tumor groups, PET/CT scores of 4 categories will also be analyzed. C-index will be calculated to evaluate the prognostic capacity of PET/CT score with survival outcomes. Additionally, the Cohen kappa coefficient will be calculated to measure inter-reader agreement.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">139</enrollment>
  <condition>Anal Squamous Cell Carcinoma</condition>
  <condition>Stage 0 Anal Cancer AJCC v8</condition>
  <condition>Stage I Anal Cancer AJCC v8</condition>
  <condition>Stage II Anal Cancer AJCC v8</condition>
  <condition>Stage IIA Anal Cancer AJCC v8</condition>
  <condition>Stage IIB Anal Cancer AJCC v8</condition>
  <condition>Stage III Anal Cancer AJCC v8</condition>
  <condition>Stage IIIA Anal Cancer AJCC v8</condition>
  <condition>Stage IIIB Anal Cancer AJCC v8</condition>
  <condition>Stage IIIC Anal Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Observational (PET/CT, medical data review, follow-up)</arm_group_label>
    <description>Patients undergo PET/CT at baseline and at 3 months post therapy completion. Patients' medical records are received. Patients are followed up for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Observational (PET/CT, medical data review, follow-up)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Health Record Review</intervention_name>
    <description>Review of medical records</description>
    <arm_group_label>Observational (PET/CT, medical data review, follow-up)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Follow-Up</intervention_name>
    <description>Undergo follow-up</description>
    <arm_group_label>Observational (PET/CT, medical data review, follow-up)</arm_group_label>
    <other_name>Active Follow-up</other_name>
    <other_name>Clinical Signs Follow-up</other_name>
    <other_name>CLSFUP</other_name>
    <other_name>Follow Up</other_name>
    <other_name>follow_up</other_name>
    <other_name>Followed</other_name>
    <other_name>Followup</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Observational (PET/CT, medical data review, follow-up)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with invasive SCCA&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed biopsy proven invasive SCCA (any T, any N) deemed a candidate&#xD;
             to undergo standard of care definitive chemoradiation at MD Anderson Cancer Center&#xD;
             (MDACC) with curative intent&#xD;
&#xD;
          -  Age &gt; 18 years at time of study entry&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unwilling to participate in a PET/CT at baseline and at 3 months post&#xD;
             completion of definitive chemoradiation&#xD;
&#xD;
          -  Patients with an active second primary malignancy requiring chemotherapy or radiation&#xD;
             treatment&#xD;
&#xD;
          -  Stage IV SCCA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benny Johnson</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benny Johnson</last_name>
    <phone>713-792-2828</phone>
    <email>bjohnson6@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benny Johnson</last_name>
      <phone>713-792-2828</phone>
      <email>bjohnson6@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Benny Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M.D. Anderson Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

